Indian drugmakers are preparing for the launch of copycat weight-loss drugs as the world moves towards ... billion market : ...

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

Susan McGowan, 58, from Lanarkshire, died from multiple organ failure, septic shock and pancreatitis after taking two ...

Use of the weight loss drug was also linked to shorter hospital stays. Eli Lilly and Novo Nordisk are the main players in the GLP-1 field, but they're facing competition from compounding pharmacies, ...

We're going to have a little bit of a read on the weight loss drug market. Last week, Eli Lilly reported earnings, provided some guidance that were below expectations due to underperformance in its ...

Novo Nordisk reported earnings, posting some chunky year-over-year growth and far outperforming its only real rival at the ...

She is now the first person in the UK whose death has officially been linked to the rising trend of weight loss jabs.

The company's latest presentation supports the idea that its lead program will make billions.

BEN Shephard awkwardly stepped in on today’s This Morning when former politician Nadine Dorries repeatedly plugged a ...

Shares in Novo Nordisk which competes with Eli Lilly in an obesity drug market that some analysts forecast could be worth about $150 billion by the early 2030s, rose nearly 9%.

At least 25% body weight loss occurred in 43% taking the highest dose ... Jastreboff reported disclosures with Amgen, ...